WVU Rockefeller Neuroscience Institute
Morgantown, West Virginia, 26505, United States
Location status: Recruiting
Location contact
James Mahoney, PhD
CONTACT
NCT Number: NCT06218706
This is a randomized, double-blind, sham-controlled, partial crossover study investigating LIFU targeting the NAc and VC for participants with severe, treatment refractory OUD.
Interested in participating?
Request Info22 year–60 year
All sexes
Interventional
Not applicable
Morgantown, West Virginia, 26505, United States
Location status: Recruiting
James Mahoney, PhD
CONTACT
The overall objective of this study is to assess the safety, tolerability, and feasibility of using Low Intensity Focused Ultrasound (LIFU) to treat opioid use disorder (OUD) as well as investigate the potential impact on substance use and risk factors associated with drug use recurrence.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The major objective of this study is to further test safety, tolerability, and feasibility of LIFU in this population as well as investigate the impact of LIFU on opioid and other substance use. The primary endpoint is 90 days (Post-LIFU Week 12) following Active/Sham LIFU. After the primary endpoint is reached, the blind will be broken and the group who received Sham LIFU will cross-over and receive Active LIFU
Time frame: Post-ExAblate Procedure through 90 day Follow-Up
Safety will be assessed by recording all adverse events that are treatment related. Each Adverse Event will be documented for patterns of occurrence.
Time frame: Post-ExAblate Procedure through 90 day Follow-Up
Changes in opioid use will be measured using quantitative urine toxicology via liquid chromatography/mass spectrometry (LC/MS).
Contact information is provided by the study sponsor or research team.
James Mahoney
CONTACT
Jennifer Marton
CONTACT
Ali Rezai
Other
A Randomized, Sham-Controlled Trial Investigating Low Intensity Focused Ultrasound as a Novel Treatment for Refractory Opioid Use Disorder
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05589181
Chemically-Induced Disorders, Mental Disorders
Newark, New Jersey, United States
View Trial DetailsNCT07064564
Chemically-Induced Disorders, Mental Disorders
Millcreek, Utah, United States
View Trial DetailsNCT06969261
Chemically-Induced Disorders, Mental Disorders
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT05511909
Anxiety, Anxiety Disorders
Baltimore, Maryland, United States
View Trial Details